Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Med J Aust ; 210(6): 281-284, 2019 04.
Article in English | MEDLINE | ID: mdl-30838677

ABSTRACT

Pregnancy is known to be a time of increased susceptibility to acquiring to human immunodeficiency virus (HIV) infection and this increased maternal risk places the unborn child at risk of vertical transmission. Pre-exposure prophylaxis (PrEP) involves the provision of antiretroviral therapy to an HIV-negative individual with ongoing risk of HIV exposure to limit the likelihood of HIV transmission. The inclusion of PrEP as part of a comprehensive strategy is recognised as an effective and safe means of reducing HIV infection in serodiscordant couples, thereby reducing the risk of vertical transmission of HIV. Current data suggest that PrEP is safe to continue during pregnancy and breastfeeding in HIV-negative women who remain vulnerable to acquiring HIV. The recent Pharmaceutical Benefits Scheme subsidisation of PrEP has reduced the financial and practical obstacles of PrEP provision, and a subsequent increase in patient awareness and acceptance of PrEP is expected. The framework for appropriately identifying and managing at-risk pregnant and lactating women requiring PrEP is poorly defined and warrants further clarification to better support clinicians and this patient group. This review discusses the current recommendations highlighting the gaps in the guidelines and makes some recommendations for future guideline development.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/prevention & control , Infectious Disease Transmission, Vertical/prevention & control , Pre-Exposure Prophylaxis , Breast Feeding , Female , Humans , Lactation , Practice Guidelines as Topic , Pregnancy
2.
Sex Health ; 9(2): 199-201, 2012 May.
Article in English | MEDLINE | ID: mdl-22498169

ABSTRACT

Self-report questionnaires on alcohol, nicotine and other drugs were administered to assess the current prevalence of alcohol, drug and nicotine use in our tertiary HIV service and inform the establishment of effective interventions. Many respondents reported use of alcohol over the preceding month (111 out of 152, 73%), and recent drug use (48 out of 137, 35%) and frequently both. Sessional alcohol consumption was prevalent among drinkers (52 out of 111, 47%), and correlated with both early treatment phase (P=0.009) and non-adherence (P=0.03). Encouraged by a notable proportion of patients expressing interest in clinic-based smoking cessation counselling, we recommend a targeted education strategy to motivate patients in health-seeking behaviours.


Subject(s)
Alcohol Drinking/epidemiology , Attitude to Health , HIV Infections/epidemiology , Smoking/epidemiology , Adult , Alcohol Drinking/psychology , Cohort Studies , Comorbidity , Female , HIV Infections/psychology , Health Promotion/methods , Humans , Male , Middle Aged , Smoking/psychology , Smoking Cessation/statistics & numerical data , Surveys and Questionnaires , Western Australia , Young Adult
3.
AIDS ; 19(9): 979-81, 2005 Jun 10.
Article in English | MEDLINE | ID: mdl-15905681

ABSTRACT

A patch test (PT) may be useful in defining true abacavir hypersensitivity syndrome (AHS). Seven previously PT-positive patients remote from the original AHS were shown to have robust 24 h responses, supporting PT durability. HLA-B*5701 was present in all seven PT-positive versus one of 11 controls tolerating abacavir (P < 0.001). Five of seven PT (71%) versus one of 11 controls (9%) (P = 0.005) showed significant abacavir-specific CD8 proliferation, suggesting a direct role for HLA-B*5701-restricted CD8 cells in the pathophysiology of AHS.


Subject(s)
Anti-HIV Agents/adverse effects , Dideoxynucleosides/adverse effects , Drug Eruptions/etiology , Reverse Transcriptase Inhibitors/adverse effects , CD8-Positive T-Lymphocytes/immunology , Drug Eruptions/diagnosis , Drug Eruptions/immunology , Genetic Predisposition to Disease , HLA-B Antigens/analysis , Humans , Patch Tests/methods
4.
Antivir Ther ; 8(4): 323-31, 2003 Aug.
Article in English | MEDLINE | ID: mdl-14518702

ABSTRACT

OBJECTIVES: To examine the in vivo effects of highly active antiretroviral therapy (HAART) regimens on adipose tissue mitochondrial DNA (mtDNA) depletion, mitochondrial organellar proliferation, and markers of adipocyte differentiation and phenotype. DESIGN AND METHODS: DNA and mRNA quantification using real-time PCR methods was performed on adipose tissue samples from 31 HIV-infected individuals, of whom 11 were treatment-naive and 20 were receiving HAART. mtDNA depletion was measured as mtDNA copies/cell, and mitochondrial proliferation by quantification of mitochondrial protein mass. Regulation of mitochondrial biogenesis was assessed by NRF-1 and mtTFA mRNA. PPARgamma, UCP2 and UCP1 mRNA expression was used to assess adipocyte differentiation and phenotype. RESULTS: Stavudine-based HAART recipients (n=10) displayed significant mtDNA depletion (12.8% of control, P<0.001), mildly increased mitochondrial protein mass (2.6-fold of control, P=0.032) and decreased expression of PPARgamma (53.9% of control, P=0.021), UCP2 (62.2% of control, P=0.024) and UCP3 (51.8% of control, P=0.047) mRNA compared with controls. Zidovudine-based HAART recipients (n=7) also displayed significant mtDNA depletion (34.45% of control, P=0.031), increased mitochondrial protein mass (5.7-fold of control, P=0.009), and markedly increased UCP1 (18-fold of control, P=0.009) mRNA. Elevated UCP1 mRNA expression was found to be associated with non-stavudine (zidovudine or abacavir), protease inhibitor (PI)-containing HAART (95-fold of non-stavudine, non-PI-containing HAART, P=0.006). CONCLUSION: Differential effects of stavudine and zidovudine therapy on mtDNA depletion and expression of adipocyte differentiation markers PPARgamma and UCP2 were observed, consistent with increased adipose tissue toxicity associated with stavudine therapy. Increased UCP1 mRNA, a marker of brown adipose tissue phenotype, was associated with non-stavudine, PI-containing HAART, and may represent an adaptive response to the increased fatty acid flux associated with PI therapy, and may contribute to the increased resting energy expenditure reported in such patients.


Subject(s)
Adipocytes/cytology , Adipose Tissue/pathology , Antiretroviral Therapy, Highly Active/adverse effects , DNA, Mitochondrial/metabolism , HIV Infections/drug therapy , Mitochondria/physiology , Adipose Tissue/metabolism , Adult , Anti-HIV Agents/adverse effects , Cell Differentiation , DNA, Mitochondrial/genetics , Dideoxynucleosides/adverse effects , HIV Protease Inhibitors/adverse effects , Humans , Male , Middle Aged , Mitochondria/pathology , Mitochondrial Proteins/metabolism , Polymerase Chain Reaction , RNA, Messenger/genetics , RNA, Messenger/metabolism , Reverse Transcriptase Inhibitors/adverse effects , Stavudine/adverse effects , Zidovudine/adverse effects
5.
J Acquir Immune Defic Syndr ; 33(1): 29-33, 2003 May 01.
Article in English | MEDLINE | ID: mdl-12792352

ABSTRACT

OBJECTIVE: HIV-1 protease inhibitors (versus no protease inhibitors) and stavudine (versus zidovudine) are independently associated with a higher risk of lipoatrophy in HIV-infected patients. We sought to determine whether the revision of stavudine and/or protease inhibitor-containing regimens to combivir/abacavir would result in prevention and/or reversibility of lipoatrophy in HIV-1-infected patients. DESIGN: The investigation was a prospective, randomized, controlled, open-label study. SUBJECTS: The subjects included 37 HIV-1-infected individuals with stable undetectable HIV-1 loads who were taking a regimen containing either stavudine or zidovudine with lamivudine and a protease inhibitor. INTERVENTION: Subjects were randomized to continue therapy or switch stavudine to zidovudine and protease inhibitor to abacavir, such that the universal switch regimen was combivir (zidovudine/lamivudine) and abacavir. MAIN OUTCOME MEASURES: Total body, leg, and arm fat mass was measured at baseline, 24 weeks, and 48 weeks using whole-body dual-energy x-ray absorptiometry. Single-cut L4 computed tomography and assays of multiple metabolic parameters were also performed. RESULTS: There was an average gain in fat mass of 0.009 kg/(leg.mo) in switch patients versus a loss of 0.010 kg/(leg.mo) in controls (p =.04, on-treatment analysis) over 48 weeks. Significant arm fat restoration was observed in patients who switched regimens, with an average gain of 0.014 kg/(arm.mo) (p =.004), whereas controls did not have a significant change from baseline. Analyses of percentage changes in arm and leg fat masses showed similar findings. No significant effects on intraabdominal fat, blood lipid levels, glycemic indices, and lactate levels were detected, although most baseline mean values were normal in study subjects. Combivir/abacavir maintained virological control in all but one case, and three (13.6%) of 22 individuals had adverse reactions to abacavir therapy. CONCLUSIONS: A switch to combivir/abacavir therapy was associated with objective evidence of limb fat-sparing and fat restoration compared with continued treatment with stavudine and/or protease inhibitor.


Subject(s)
Dideoxynucleosides/therapeutic use , HIV Infections/complications , HIV Protease Inhibitors/therapeutic use , HIV-Associated Lipodystrophy Syndrome/complications , HIV-Associated Lipodystrophy Syndrome/prevention & control , Lamivudine/therapeutic use , Stavudine/therapeutic use , Zidovudine/therapeutic use , Adult , Body Composition/drug effects , Dideoxynucleosides/adverse effects , Drug Combinations , Drug Therapy, Combination , Female , HIV Infections/drug therapy , HIV Protease Inhibitors/adverse effects , HIV-Associated Lipodystrophy Syndrome/chemically induced , Humans , Lamivudine/adverse effects , Male , Middle Aged , Stavudine/adverse effects , Zidovudine/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...